



Biotech Daily

Wednesday September 23, 2026

Daily news on ASX-listed biotechnology companies

- * ASX EVEN, BIOTECH DOWN: MICRO-X UP 60%; PROTEOMICS DOWN 15%
- * CONTROL BIONICS: TOBII DYNAVOX GERMAN DISTRIBUTOR
- * PARADIGM HALTS PHASE III PPS FOR KNEE OA TRIAL; SUSPENSION
- * KINOXIS RAISES \$6.75m; DR ELAINE STEAD DIRECTOR
- * ROYAL WOMEN'S HOSPITAL TRIALS siRNA FOR PRE-ECLAMPSIA
- * GARVAN: BOWEL INFLAMMATION MIGHT INCREASE COLON CANCER RISK
- * PRESCIENT SHARE PLAN RAISES \$6m
- * ACTINOGEN OPTIONS UNDERWRITING RAISES \$987k; TOTAL \$4.8m
- * DIMERIX DRAWS \$17m OF \$34m SKIPTAN, OTHERS LOAN
- * ADALTA, FDA MEET ON EW-001 FOR MESOTHELIOMA 'THIS YEAR'
- * BCAL TO DISTRIBUTE CLEAR NOTE'S EARLY CANCER TESTS
- * PATRYS DOSES 1st PHASE Ia RLS-2202 PARTICIPANT
- * ACTINOGEN LAST ALZHEIMER'S PATIENT VISIT; NOVEMBER RESULTS
- * TRUSCREEN: 3 UNITAID PROPOSALS 'NOT SELECTED'
- * GENETIC SIGNATURES: 'BCAL BOARD SPILL EGM'
- * COCHLEAR \$1.4m CEO DIG HOWITT RIGHTS, OPTIONS AGM
- * LTR 4m DIRECTOR OPTIONS AGM
- * MICRO-X PLEADS 'RETURN TO JUNE LEVELS' TO ASX 50% QUERY
- * EBR: HESTA TAKES 6%, HOST PLUS TAKES 18%
- * DAVID PARADICE, PARADICE INVESTMENT TAKE 7% OF ARTRYA
- * PRO MEDICUS APPOINTS TIM REED DIRECTOR

MARKET REPORT

The Australian stock market edged up 0.09 percent on Wednesday September 23, 2026, with the ASX200 up 7.5 points to 8765.3 points. Fourteen of the Biotech Daily Top 40 companies were up, 17 fell, eight traded unchanged and one was untraded.

Micro-X was the best for the third day in a row (see ASX query, below), up 1.8 cents or 60.0 percent to 4.8 cents, with 5.0 million shares traded. Atomo climbed 8.8 percent; Curvebeam and Orthocell were up more than seven percent; Avita improved 5.65 percent; Nova Eye and Optiscan were up more than three percent; 4D Medical and Medical Developments rose more than two percent; Aroa and Artrya were up one percent or more; with Clinuvel, Mesoblast, Resmed and Starpharma up by less than one percent.

Proteomics led the falls, down two cents or 14.8 percent to 11.5 cents, with 610,681 shares traded. Imugene lost 6.4 percent; Botanix was down 5.3 percent; Amplia, Lumos, Syntara and Telix fell four percent or more; Cyclopharm was down 3.1 percent; Clarity, Dimerix, Nanosonics and Saluda shed more than two percent; Emvision, Imricor, Neuren, Prescient and Pro Medicus were down more than one percent; with Cochlear, CSL and Racura down by less than one percent.

CONTROL BIONICS

Control Bionics says the Stockholm-based Tobii Dynavox GmbH has been appointed German distributor of its Neuronode sensor converting electrical signals to devices. Control Bionics said Germany was “one of the largest augmentative and alternative communication markets globally and among the largest in Europe” and Tobii Dynavox was “one of the world’s largest providers of assistive communication technology”.

The company said its Neuronode wireless, wearable sensor detected “small electrical signals generated when a user attempts a muscle movement, together with spatial movement, and converts them into a reliable switch input”; allowing a person with severe motor impairment to operate a speech-generating device, computer or tablet, and was used with an eye-gaze system where the user retained only minimal voluntary movement. The company said Neuronode had Conformité Européenne (CE) mark and was cleared by the US Food and Drug Administration and Australian Therapeutic Goods Administration. Control Bionics said training of Tobii Dynavox’s German sales organization had begun, with the first regional team trained and the balance to be scheduled progressively. The company said that the non-exclusive agreement had an initial term of 12 months, with no minimum purchase or minimum revenue commitment.

Control Bionics managing-director Jeremy Steele said that Germany was a deliberate focus and Neuronode was listed in the Hilfsmittelverzeichnis (HMFV or German Medical Aids Directory) earlier this year.

“That listing was the hard part,” Mr Steele said. “It validates the technology against an independent standard, and it means a German clinician can prescribe the Neuronode knowing there is a funded route for their client.”

“What we needed next was reach, and Tobii Dynavox gives us that,” Mr Steele said.

“It is the same wholesale model we are executing in the US - putting the device in the hands of partners who are already in front of the clinician at the point of assessment,” Mr Steele said. “Reimbursement decisions in Germany take time, and we would rather let the volumes speak for themselves.”

Control Bionics was unchanged at 5.8 cents.

PARADIGM BIOPHARMACEUTICALS

Paradigm says it has halted its phase III trial of injectable pentosan polysulfate sodium or Zilosul for knee osteoarthritis.

Paradigm said that the independent data safety monitoring board (DSMB) confirmed that the interim efficacy result “did not reach the pre-specified threshold required for the study to continue”.

In June, Paradigm said it had enrolled 538 of a hoped-for 466 patients in its phase III trial of injectable PPS for knee osteoarthritis pain (BD: Jun 15, 2026).

Today, Paradigm said the outcome followed the review of unblinded interim efficacy and safety data, while its staff remained “blinded to treatment allocation, the actual treatment effect size and the underlying treatment-group results”.

The company said that the planned interim analysis was conducted after about 50 percent of participants reached the day-112 primary efficacy endpoint.

Paradigm said that “the observed treatment effect fell below the minimum efficacy threshold for continuation under the study’s statistical design, indicating that the study is unlikely to meet its primary efficacy endpoint at the final analysis”.

The company said that “operational challenges during the trial resulted in a significant amount of missing data, which has impacted the interim efficacy results”.

Paradigm said it continued “to review the available data to obtain further information and better understand the nature and extent of that impact”.

The company said it would with the DSMB, its clinical partners and investigators to determine the appropriate remaining study activities and database processes; and following completion of the required database and unblinding processes, it would “undertake a detailed review of the available phase III data, including pain, function, safety and other pre-specified endpoints ... [to assess] the outcome and the next steps”.

Paradigm executive chairman Paul Rennie said “the Board and the entire Paradigm team are deeply disappointed by this outcome”.

“We recognize the disappointment it brings to our shareholders and everyone who has supported the program,” Mr Rennie said.

“An initial review, by Paradigm’s unblinded clinical staff, identified missing data,” Mr Rennie said. “Under the statistical analysis plan, missing data is imputed and this imputation impacted the efficacy outcome.”

“This is very disappointing given our broad and positive experience with iPPS in treating osteoarthritis,” Mr Rennie said.

“We remain optimistic in the therapeutic potential of PPS in treating osteoarthritis,” Mr Rennie said.

“Paradigm retains a substantial intellectual property portfolio,” Mr Rennie said.

“We are assessing the best path forward,” Mr Rennie said.

Paradigm said it would “reassess the timing, scope and objectives of future regulatory engagement following the data review”.

The company said that following the interim analysis outcome, it would assess the implications for its financial position and future operations, including potential trial wind-down costs, remaining contractual commitments, future funding requirements and the company’s rights and obligations under its existing funding arrangements.

Paradigm said it was working closely with secured convertible note facility provider Obsidian Global to assess the implications of the trial outcome under the facility.

Paradigm said it had requested a voluntary suspension while it assesses the financial implications of the trial outcome and progresses discussions with Obsidian.

The company said the suspension was expected to continue to September 28, 2026.

Paradigm last traded at 24.5 cents.

KINOXIS THERAPEUTICS

Kinoxis says it has raised \$6.75 million, with \$1.75 million from existing investors and \$5 million from new investor Main Sequence, with Dr Elaine Stead appointed a director. Yesterday, the Brandon Biocatalyst Cureator program said Melbourne's Kinoxis was awarded \$2,500,000 for its treatments for chronic agitation and aggression associated with dementia, from the partnership with Dementia & Cognitive Decline, Australia's National Digital Health Initiative (AND Health) and Dementia Australia, funded by the Federal Government Medical Research Future Fund (BD: Sep 22, 2026).

Last night in a media release, Kinoxis said that its first-in-class therapeutics targeted ALOX15 "for high-need central nervous system indications".

The company said the \$6.75 million and the Cureator grant provided capital to advance the ALOX15 inhibitor programs and brought "a new partner with deep experience supporting Australian companies built around differentiated science and transformative technologies".

According to the Commonwealth Scientific and Industrial Research Organisation website, Main Sequence Ventures was "founded by [the] CSIRO in 2017 to address the 'valley of death' between research and commercialization".

Kinoxis said that the funds would support the development of its "long-acting ALOX15 inhibitor KNX101 as a potential new treatment for chronic agitation and aggression associated with dementia".

The company said it was developing "brain-penetrant small-molecule inhibitors of ALOX15, an intracellular enzyme that drives circuit dysregulation, neuroinflammation and neurodegeneration" and the primary areas of development were agitation associated with dementia and pain.

Kinoxis said that its lead program, KNX100, was a rapid, short-acting small-molecule inhibitor of ALOX15 being evaluated in a phase II trial for both targeted management of persistent agitation and rapid treatment of acute agitation episodes associated with dementia.

The company said that the trial had recruited half its target, "with topline data expected mid-2027".

Kinoxis said that the 'Cares-X' study had expanded recruitment into hospital dementia wards and residential aged care facilities, "broadening access to people living with more advanced dementia and more frequent or severe agitation, complementing the study's existing community-based recruitment pathway".

The company said that it was "developing a suite of next-generation, long-acting ALOX15 inhibitors designed for the treatment of acute and chronic pain, as well as chronic agitation associated with dementia".

Kinoxis said that lead optimization was "nearing completion, with [US Food and Drug Administration investigational new drug application]-enabling toxicology studies planned to commence on the lead candidate KNX101 by the end of 2026.

The company said that in connection with Main Sequence's investment, Dr Elaine Stead would join the Kinoxis board.

Kinoxis said that Dr Stead was "a venture capitalist, entrepreneur and scientist with extensive experience in healthcare innovation, venture investment and technology commercialization.

The company said that Dr Stead was a member of the investment team at Main Sequence, where she focused on investing in transformative healthcare technologies.

According to the Main Sequence website, Dr Stead held a Bachelor of Science and a Doctor of Philosophy both from the University of Adelaide.

Kinoxis is a private company.

ROYAL WOMEN'S HOSPITAL

Melbourne's Royal Women's Hospital is trialing a small interfering RNA (siRNA), to reduce overproduction of the sFlt1 protein, thought to play a role in pre-eclampsia.

The Royal Women's Hospital said that the phase Ib trial was "the first time the treatment has been administered during pregnancy and focuses on assessing safety and determining the appropriate dose for future research".

The Hospital said the only treatment for severe pre-eclampsia was to end the pregnancy and deliver the baby, even if the mother was only partway through her pregnancy.

The RWH said that "despite decades of research, treatment options for pre-eclampsia have changed little" and the drug being tested was "developed by US biotechnology company Comanche Biopharma", based in Concord, Massachusetts.

The Hospital said it was "the first site ... to enrol and treat a participant in the trial and was selected because of its expertise in pre-eclampsia care, research and high-risk maternity services".

The RWH said that pre-eclampsia was characterized by high blood pressure and signs of maternal organ dysfunction, usually developing after 20 weeks' pregnancy.

The Hospital said that pre-eclampsia could affect a mother's kidneys, liver, blood clotting system, brain and placenta, might restrict a baby's growth and could lead to eclampsia, a life-threatening convulsive disorder.

The RWH said pre-eclampsia increased a woman's later-life risk of cardio-vascular disease and premature death and affected about five percent of pregnancies.

GARVAN INSTITUTE OF MEDICAL RESEARCH

The Garvan says cellular differences between two similar bowel diseases identified immune activity that may explain why one has a much higher risk of colon cancer.

The Garvan said the two closely related bowel diseases, primary sclerosing cholangitis (PSC) and ulcerative colitis were treated the same way, but were fundamentally different.

The Institute said PSC was a chronic liver disease affecting about 1,000 Australians that blocked bile ducts and caused liver scarring, with about 70 percent of patients also having a form of inflammatory bowel disease (IBD) resembling ulcerative colitis.

The Garvan said despite similarities, people with PSC had less severe flares but faced a colorectal cancer risk three times higher than those with ulcerative colitis alone.

The research, titled 'Primary sclerosing cholangitis displays distinct colonic mucosa topography yet a shared mast cell state with ulcerative colitis' was published in Nature Communications and is at: <https://www.nature.com/articles/s41467-026-75231-1>.

The Garvan Institute said that the combination of a "milder-looking disease with much greater cancer risk, has long puzzled researchers".

The Garvan said it showed that the gut of people with PSC-associated IBD had a distinct microbiome and showed a higher level of immune activity, even in the absence of inflammation, or 'flare-ups'.

The Garvan said it compared biopsies from eight patients with PSC-associated IBD, 11 patients with ulcerative colitis alone, and 10 people with no gastro-intestinal disease.

The Institute said the researchers used single-cell sequencing, spatial mapping and microbiome analysis to provide a comprehensive comparison of the conditions.

The Garvan said it found that in tissue that a pathologist had inspected under a microscope and classified as free from inflammation, there was a build-up of cytotoxic, or cell-killing, immune cells in the colon of patients with PSC-related bowel disease.

"These cells are a normal part of the immune system, but finding them so concentrated in tissue that would otherwise be considered 'normal' was unexpected," the Garvan said.

PRESCIENT THERAPEUTICS

Prescient says that it raised \$4,798,108 in its share plan at 6.5 cents a share with a further \$1,203,700 in a follow-on placement.

Last month, Prescient said it hopes to raise \$7 million at 6.5 cents a share in a share plan to fund development of its cancer treatment PTX-100 (BD: Aug 25, 2026).

At the time, Prescient said the funds would be used for business development and portfolio management activities, including the evaluation of pipeline opportunities.

Prescient fell 0.1 cents or 1.5 percent to 6.7 cents with 2.1 million shares traded.

ACTINOGEN MEDICAL

Actinogen says it has raised a further \$986,839, through the issue of 26,315,700 shortfall shares at 3.75 cents each to options underwriter Forrest Capital.

Earlier this month, Actinogen said that Forrest Capital would underwrite \$4,771,337 in two tranches of unlisted options (BD: Sep 1, 2025).

An Actinogen executive told Biotech Daily the balance of the options had been exercised by investors, between the underwriting agreement and the expiry of the options.

Actinogen was unchanged at 5.8 cents with 14.2 million shares traded.

DIMERIX

Dimerix says it has drawn \$17 million of the \$34 million in the loan from Skiptan Pty Ltd and unnamed other Australian and US lenders.

Earlier this month, Dimerix said it had the loan from Skiptan and unnamed others and in July, said it had a \$10 million loan with the shareholder Peter Meurs-associated Skiptan Pty Ltd at 10 percent a year interest to fund potential commercial manufacturing and marketing approval for DMX-200 (BD: Jul 17, Sep 4, 2026)

Dimerix fell half a cent or 2.1 percent to 23.5 cents with 2.1 million shares traded.

ADALTA

Adalta says the US Food and Drug Administration has accepted its request for a pre-investigational new drug application (IND) meeting for EW-001 for cancer this year.

Adalta's said EW-001 was a chimeric antigen receptor (CAR)-T cell therapy for advanced mesothelioma and other mesothelin-expressing cancers.

The company said the meeting would be it "first significant engagement with the FDA on EW-001 and is a key milestone".

Adalta said that the pre-IND meeting was "a formal opportunity to put a development plan in front of FDA reviewers and get their feedback before the most expensive parts of that plan are committed".

Adalta managing-director Dr Tim Oldham said meeting the FDA was "the headline [but] what matters more is what it took to reach the point where we could request the meeting".

"Our team has worked through hundreds of documents ... covering how EW-001 is made, how it is tested and how it has performed in patients in China," Dr Oldham said.

"We have worked with some of Australia's most experienced CAR-T and mesothelioma clinicians to turn that into a draft phase I clinical trial protocol," Dr Oldham said.

"Now, consistent with our capital efficient approach, we get to test our thinking with the world's most experienced regulator of cell therapies before we commit to the costliest parts of the program," Dr Oldham said.

Adalta was up 0.05 cents or 14.3 percent to 0.4 cents with 2.3 million shares traded.

BCAL DIAGNOSTICS

Bcal says it will distribute the San Diego, California-based Clear Note Health's Avantect multi-cancer early detection test.

Bcal said the test showed sensitivity of 56.2 percent and specificity of 98.4 percent "across all analyzed cancers" and would complement the Avantect ovarian cancer test, the Avantect pancreatic cancer test and its own Breastest Plus for breast cancer.

The company said that the Avantect multi-cancer test was blood-based and looked for cancer-associated signals in eight cancers, providing "a likely organ-of-origin signal" for lung, pancreatic, liver, ovarian, gastric, oesophageal, breast and colorectal cancer.

Bcal said that for a validation study blood samples from Australian patients would be collected and initially analyzed in Clear Note Health's laboratory.

The company said that a phased rollout would use its national clinical and referral infrastructure ahead of broader release.

Bcal said the initial introduction would be in Sydney and Melbourne, "supported through telehealth and in-person consultation".

Bcal chief executive officer Anne-Louise Arnett said cancer diagnostics was "increasingly toward earlier, less-invasive detection, and blood-based testing has a role to play in that shift".

"Avantect multi-cancer expands our commercial portfolio and provides an opportunity to leverage our existing national infrastructure to build a broader early detection business," Ms Arnett said.

Bcal fell 0.1 cents or 1.22 percent to 8.1 cents.

PATRYS

Patrys says it has dosed the first of up-to 16 participants in its phase Ia trial of RLS-2202, which is intended as a treatment for acute care delirium.

Patrys chief executive officer Dr Samantha South told Biotech Daily that there were four health volunteers in the first cohort with a further 12 expected to participate in the second cohort.

The company said that dosing "marks RLS-2202's transition into human clinical evaluation, with the study now generating clinical data to inform the next stage of the program".

Patrys said the phase Ia study was "a bridging trial designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of RLS-2202 in healthy adult volunteers".

The company said that cohort 1 would receive both the reference oral formulation of quetiapine and RLS-2202, separated by a four-day washout period.

Patrys said the study used a dose-escalation design, with progression between the two cohorts subject to review by an independent safety review committee.

The company said that the primary objective was to assess the safety and tolerability of RLS-2202, with secondary objectives pharmacokinetic profile and dose levels to support subsequent clinical development.

Patrys said that quetiapine had "an extensive history of oral use in the treatment of schizophrenia and bipolar disorder".

The company said that RLS-2202 was being developed as an intra-venous (IV) formulation, "with the objective of providing an alternate, faster and safer, route of administration for patients with delirium in acute-care".

Patrys said the study would assess whether there were "any clinically meaningful differences from the established profile of oral quetiapine".

Patrys fell 0.1 cents or three percent to 3.2 cents.

ACTINOGEN MEDICAL

Actinogen says following the last of 247 Alzheimer's disease patient visits in its phase IIb/III Xanamem trial, topline results are on track for November.

Actinogen said that the Xanamem trial of oral Xanamem (emestadastat) was a randomized, double-blind, placebo-controlled pivotal trial comparing Xanamem 10 mg to placebo treatment over 36 weeks, to reduce the stress hormone cortisol.

The company said that selecting the participants with elevated pTau181 was "a key feature of the trial, using a clinically validated blood test instead of more complex methods such as amyloid brain scans or cerebrospinal fluid biomarkers to diagnose [Alzheimer's disease]".

TRUSCREEN GROUP

Truscreen says that three proposals submitted in April 2026 to funder Unitaid "were not selected for further development on this occasion".

Truscreen said the proposals were submitted in April 2026 in response to Unitaid's 'Call for Proposals: Accelerating Cervical Cancer Elimination through Secondary Prevention in Low and Middle Income Countries'.

According to Wikipedia Unitaid is hosted by the World Health Organization, based in Geneva, and was established by Brazil, Chile, France, Norway and the UK.

Truscreen said that its efforts and engagement were acknowledged, and the company was encouraged to respond to future cervical cancer elimination Calls for Proposals.

The company said its three proposals were: 'Sub Saharan Africa Scale-Up'; 'African Screen-and-Treat Program'; and 'Asia-Pacific & Latin America Scale up'.

"While these Truscreen led proposals would not proceed, their development strengthened key relationships with a consortium of internationally recognized implementation [non-government organization] partners, with which the company intends to partner," Truscreen said.

The company said its cervical cancer screening technology was "ideally suited for low and middle income countries".

Truscreen said it was the technology provider to a Unitaid grant application by a global non-government organization (NGO), which remained under consideration.

Truscreen was unchanged at 1.1 cents with 1.45 million shares traded.

GENETIC SIGNATURES

Genetic Signatures says it opposes a Bcal call to replace directors Michael Aicher and Dr Jenny Harry with John Melki and Susan Forrester.

Earlier this month, Genetic Signatures said that it had received a section 249D notice from Bcal which wanted to replace Genetic Signatures chair Mike Aicher with former Genetic Signatures chief executive officer John Melki and appoint Susan Forrester as a director (BD: Sep 3, 2026).

In August, Bcal said it had increased its holding in Genetic Signatures to 41,923,644 shares (18.46%) (BD: Aug 26, 2026).

The meeting will be held at the offices of Gadens, Level 29, 8 Chifley Square, Sydney on October 28, 2026 at 10am (AEDT).

Genetic Signatures was up 0.3 cents or four percent to 7.8 cents.

COCHLEAR

Cochlear will vote to grant chief executive officer Dig Howitt up to \$1,355,871 in 9,924 performance rights and 32,084 options, exercisable at \$136.62 each.

Cochlear's notice of meeting said shareholders would vote on the remuneration report, the re-election of directors Michael Daniell and Prof Bruce Robinson and the proportional takeover provisions.

The meeting will be held virtually and at Cochlear, 1 University Avenue, Macquarie University, Sydney, on October 24, 2026 at 10am (AEDT).

Cochlear fell 39 cents or 0.3 percent to \$140.69 with 335,520 shares traded.

LTR PHARMA

LTR says its annual general meeting will vote to grant three directors 4,000,000 options exercisable at 67.4 cents within four years.

LTR said that shareholders would vote to issue 2,000,000 options to chair Lee Rodne and 1,000,000 options each to directors Dr Julian Chick and Maja McGuire.

The company said that shareholders would vote on the remuneration report, the re-election of director Mr Rodne, the 10 percent placement capacity, the readoption of the employee incentive plan, and the renewal of proportional takeover provisions.

The meeting will be held at K&L Gates, 16/66 Eagle Street, Brisbane, on October 23, 2026 at 2pm (AEST).

LTR fell 1.5 cents or 3.1 percent to 46.5 cents.

MICRO-X

Micro-X has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 50.0 percent from 3.0 cents on September 22 to 4.5 cents today, September 23, 2026 but did not note an increase in the trading volume.

Micro-X said the increase "has seen the share price return to levels last seen in June 2026".

Micro-X was up 1.8 cents or 60.0 percent to 4.8 cents with five million shares traded.

EBR SYSTEMS

EBR says that substantial shareholders Hesta and Host Plus have increased to 6.2 percent and 18.1 percent, respectively.

EBR said that Hesta (Health Employees Superannuation Trust Australia) increased from 37,246,781 CDIs (4.95%) to 52,350,861 CDIs (6.19%).

The company said that Host Plus (originally Hospitality Superannuation Trust) increased from 76,259,609 CDIs (10.12%) to 153,260,799 CDIs (18.12%).

The company previously said that THE Medical Research Commercialisation Fund 3 (MRCF3) managed funds on behalf of Hesta, Host Plus and Brandon Capital (BD: Jul 16, 2026).

EBR was unchanged at 26.5 cents.

ARTRYA

David Paradice says with Paradice Investment Management Pty Ltd he has increased his holding in Artrya from 7,905,758 shares (5.001%) to 11,387,931 shares (6.9679%). Sydney's Mr Paradice said that traded shares between March 3 and September 18, 2026, with the single largest purchase 2,599,014 shares on September 18, for \$10,203,664 or \$3.926 a share.

Artrya was up five cents or 1.3 percent to \$3.87 with two million shares traded.

PRO MEDICUS

Pro Medicus says it has appointed Tim Reed as an independent non-executive director, effective from October 1, 2026.

Pro Medicus said that Mr Reed had more than 30 years' experience in technology, strategy, business development and investment.

The company said that Mr Reed was the chief executive officer of MYOB from 2008 to 2019, was co-managing director of Potentia Capital and was currently a director of Transurban, a member of the Australian Government's Climate Change Authority and was previously the head of the Business Council of Australia.

Pro Medicus said that Mr Reed held a Bachelor of Commerce from the University of Melbourne and a Master of Business Administration from Harvard Business School.

Pro Medicus fell \$3.02 or 1.8 percent to \$161.31 with 183,479 shares traded.